While there is support for the effectiveness of glinides in HNF1A-diabetes as an alternative to SU, particularly to address hypoglycemia2631,45, and for the newer diabetes medications as monotherapy (GLP1RA)27,30,43 or augmentative therapy (DPP4i)21,28,32,34,37,39, studies are of short duration and limited in number. The gene discussed is HNF1A; the disease is diabetes mellitus.